Several lines of evidence support a role for brain-derived neurotrophic factor (BDNF) alterations in the etiology of eating disorders (EDs). BDNF heterozygous knockout mice show alterations in eating behavior, increased body weight and adipocyte hypertrophy. BDNF also regulates the synaptic efficiency through the modulation of key neurotransmitter systems previously known to be involved in ED. These findings, together with the fact that this neurotrophin is expressed in the hypothalamus nuclei associated with weight regulation and feeding control, led us to propose BDNF as a candidate gene for ED. To investigate the possible involvement of this neurotrophin in eating behavior, we screened the BDNF gene in 95 ED patients and identified four sequence variants. Two of them, À374A/T and À256G/A, were found in two patients with anorexia nervosa (AN) and consisted of single-nucleotide mutations within the 5 0 untranslated region (5 0 UTR). The other two polymorphisms resulted in a C to T transition located at the 5 0 UTR of the BDNF gene and an amino-acid substitution within the BDNF precursor protein (Val66Met). We performed a case-control study for these two Single-nucleotide polymorphisms in a sample of 143 ED patients and 112 unrelated controls and found a strong association of restricting AN (ANR) with the Met allele of the Val66Met BDNF polymorphism (2p ¼ 0.002). There was also evidence for a significant effect of this sequence variant on the minimum body mass index (MBMI) (2p ¼ 0.006). These results suggest that the BDNF Met66 variant may be a susceptibility factor to ED, mainly to ANR and low MBMI.
Several lines of evidence support a role for brain-derived neurotrophic factor (BDNF) alterations in the etiology of eating disorders (EDs). BDNF heterozygous knockout mice show alterations in eating behavior, increased body weight and adipocyte hypertrophy. BDNF also regulates the synaptic efficiency through the modulation of key neurotransmitter systems previously known to be involved in ED. These findings, together with the fact that this neurotrophin is expressed in the hypothalamus nuclei associated with weight regulation and feeding control, led us to propose BDNF as a candidate gene for ED. To investigate the possible involvement of this neurotrophin in eating behavior, we screened the BDNF gene in 95 ED patients and identified four sequence variants. Two of them, À374A/T and À256G/A, were found in two patients with anorexia nervosa (AN) and consisted of single-nucleotide mutations within the 5 0 untranslated region (5 0 UTR). The other two polymorphisms resulted in a C to T transition located at the 5 0 UTR of the BDNF gene and an amino-acid substitution within the BDNF precursor protein (Val66Met). We performed a case-control study for these two Single-nucleotide polymorphisms in a sample of 143 ED patients and 112 unrelated controls and found a strong association of restricting AN (ANR) with the Met allele of the Val66Met BDNF polymorphism (2p ¼ 0.002). There was also evidence for a significant effect of this sequence variant on the minimum body mass index (MBMI) (2p ¼ 0.006). These results suggest that the BDNF Met66 variant may be a susceptibility factor to ED, mainly to ANR and low MBMI. Keywords: anorexia; bulimia; brain-derived neurotrophic factor; BDNF; single-nucleotide polymorphism Eating disorders (EDs) are complex and multifactorial, with the involvement of both psychosocial and biological factors. [1] [2] [3] [4] [5] [6] A genetic contribution in ED is widely accepted [6] [7] [8] [9] and genes involved in eating behavior, weight regulation, satiety and metabolism, as well as those under hormonal control are considered candidate genes for their role in anorexia nervosa (AN) and bulimia nervosa (BN). Among these candidates, we propose brain-derived neurotrophic factor (BDNF), which encodes for a neurotrophic factor with an essential role in neuronal survival and differentiation, and is also involved in synaptic efficiency and neuronal plasticity. [10] [11] [12] [13] BDNF maps to 11p13-p14 14 and, although the structure of the coding exon is well known, 15 the genomic organization of the 5 0 noncoding exons has not been described. Several lines of evidence indicate a role of this neurotrophin in eating behavior and suggest that alterations in its function or expression pattern could be considered susceptibility factors to ED. To test this hypothesis we have characterized the genomic structure of the human BDNF gene. BDNF is composed of, at least, four 5 0 nontranslated exons and a single 3 0 coding exon (exon 5; Figure 1b ). Since mRNA transcripts were different at their 5 0 ends, we determined the existence of four 5 0 untranslated exons that give rise to four distinct mRNA isoforms (named A, B, C and D), as previously described in the rat BDNF gene. 16, 17 Exon 1 generates the mRNA isoform A and is 85% identical to the rat exon 3. Exon 2 gives rise to the mRNA isoform B and corresponds to a previously described promoter region of the human BDNF gene. 18 Moreover, mRNA and EST sequences gi: 1336884 and gi: 179404 revealed the presence of two other exons (exons 3 and 4); while isoform C results from alternative splicing of exon 4, the 5 0 region of isoform D corresponds to both exons 3 and 4.
In order to identify sequence variants, we screened the BDNF gene by PCR-SSCP in 95 patients with ED. By sequencing the PCR products showing aberrant SSCP patterns, four nucleotide variants were identified ( Figure 1a) . We first detected a T to A transversion in exon 3 located 374 bp upstream from the BDNF coding region. This sequence variant does not affect any consensus sequence and was found in heterozygosity in a patient with ANR (22 years, minimum body mass index (MBMI) 17.2 kg/m 2 , age of onset of weight loss (AAOC) 17 years and age of onset of amenorrhea (AAOA) 18 years). The second change identified within exon 3 consisted of a G to A transition located 256 bp upstream from the BDNF coding region. This variant affects the splicing donor consensus site and was found in heterozygosity in a patient with binge-eating/purging anorexia (ANBP; 37 years, MBMI 11.5 kg/m 2 , and AAOC 18 years). We genotyped 65 unrelated controls for these two muta- tions but none of them was detected. The third sequence variant was a previously described singlenucleotide polymorphism (SNP) consisting of a C to T transition within exon 2, located 270 bp upstream from the BDNF coding region. 19 This SNP does not affect any consensus site and was found in 8% of the ED patients. We also detected a previously described SNP consisting of a missense change (196G/A, Val66Met) 15 in the coding exon of the BDNF gene, which was present in 44% of patients with ED.
A case-control study was carried out to determine the potential role of these two SNPs in ED. The initially screened group was increased to a total sample of 143 patients. This group and 112 unrelated controls matched for ethnicity and sex were genotyped for the À270C/T and Val66Met SNPs. A power analysis was performed and revealed a statistical power of 99 and 100% for the À270C/T and Val66Met SNPs, respectively. Under the hypothesis that BDNF may confer susceptibility to the ED subtypes in different ways and to reduce heterogeneity, our patients were subdivided into four main diagnostic groups that have been shown to differ in various biological and psychopathological features. [20] [21] [22] Thus, AN, ANR, ANBP and BN diagnoses were separately considered in the statistical analyses.
To examine the association of both BDNF SNPs with ED, we compared allele and genotype frequencies between the patient and control groups. Both polymorphisms followed a distribution in HardyWeinberg equilibrium. No significant associations were found in any of the ED groups when both allele and genotype frequencies of the À270C/T SNP were considered. Nevertheless, genotype frequencies of the Val66Met polymorphism did significantly differ between the ED (w 2 ¼ 8. Table 2) . After the most conservative multiple comparison correction, the Met66 variant was still positively associated with ANR, but no associations were found in any of the other groups. Haplotype analysis gave no significant P-values (P ¼ 0.13 for the model-free analysis and P ¼ 0.11 for the heterogeneity model). No linkage disequilibrium between both BDNF SNPs was observed when ED patients (w 2 ¼ 2.22; P ¼ 0.69) or controls were considered (w 2 ¼ 0.63; P ¼ 0.97). This lack of linkage disequilibrium may explain why we observed association of ANR with the Val66Met but not with the À270C/T SNP.
We also examined the relation between the Val66-Met variant and ED-related phenotypes, such as MBMI and AAOC (Table 3) . Thus, mean scores were compared between ED subjects carrying the Met66 allele and those homozygous for the wild-type allele of the Val66Met variant. While no significant effect on AAOC was observed, the mean MBMI was significantly lower in the Met66 carriers than in noncarriers (P ¼ 0.006).
The major finding of this study is a strong association of ANR and low MBMI with the Met66 allele of the Val66Met BDNF polymorphism. These results support our initial hypothesis about a contribution of BDNF to alterations in eating behavior and body weight regulation. Two different mechan- isms could explain this association. First, the Met66 variant could be in linkage disequilibrium with a yet unknown nearby susceptibility gene directly involved in ANR or low MBMI. Alternatively, as it is located in the prodomain of the BDNF precursor this variant itself could exert a direct biological action and be a susceptibility factor to ED. Thus, the Met66 allele could genetically determine alterations in its function or stability, in the folding of the mature protein, 23, 24 in its sorting to either constitutive or regulated secretor pathways or in the neurotrophin spatio-temporal expression pattern. Moreover, the BDNF Met66 variant could also determine variations in the biosynthesis and the post-translational processing of the BDNF precursor. 25 The role of BDNF in ED is unknown, but several lines of investigation suggest that increases in the levels of this neurotrophin could be involved in some ANR characteristics, such as dietary restriction behaviors and body weight reduction. Thus, BDNF heterozygous 'knockout' mice develop obesity, showing eating behavior alterations, increased body weight and adipocyte cellular hypertrophy. 1 These results, together with the fact that BDNF increases extracellular serotonin levels 3, 4, 26 and that its expression is under estrogen control, 27, 28 suggest that BDNF variants associated with ANR may lead to a gain-of-function related to increases in the neurotrophin levels, function or stability. BDNF could influence the susceptibility to ANR and low MBMI through direct effect on food consumption and control of body weight, as it is expressed in the hypothalamic centers involved in these activities. Alternatively, since BDNF has also a key role in the modulation of different neurotransmitters, it could indirectly participate in ANR and low MBMI through changes in these systems previously involved in ED. [2] [3] [4] [5] The contribution of distinct susceptibility factors to the different ED subtypes, which is supported by other studies where differential personality and psychopathological traits were found between purging (ANBP or BN) and nonpurging ED (ANR), [20] [21] [22] Neither association was found in any ED group when the À270C/T SNP was considered, suggesting that it may not be involved in eating behavior alterations. Nevertheless, it would be necessary to test it in a larger sample because of its low frequency in the studied populations. The other two BDNF variants identified in two AN patients, À374A/T and À256G/ A, were located at the 5 0 noncoding region and could also be involved in the modulation of stability, transcription levels or expression pattern of the BDNF isoforms. Moreover, À256G/A may be implicated in the splicing function as it affects the splicing donor site of exon 3.
In conclusion, the results of our study suggest that the BDNF Met66 variant may be involved in the susceptibility to ED and that its participation is highly significant in ANR and low MBMI. However, they should be considered as preliminary until replicated in larger samples, other populations and family trios to avoid population stratifications that lead to false-positive associations. Once we confirm this association, functional studies will be necessary to determine mechanisms by which alterations in the BDNF system could contribute to the development of the ED.
Materials and methods

Study subjects
The clinical sample consisted of 143 Spanish Caucasian patients with ED that were consecutively admitted in the Psychiatric Unit of the Hospital de Bellvitge between April 1999 and December 2001. The group consisted of 70 BN cases (49%; 63 bingeeating/purging vs seven nonpurging subtype), 64 AN cases (45%; 36 bingeing/purging, 26 restricting subtype and two anorexia cases with insufficient time elapsed (o3 years restricting illness) to classify them as restricting or binge-eating/purging subtype) and nine patients with ED not otherwise specified (EDNOS; 6%). All subjects fulfilled DSM-IV criteria for these disorders (APA, 1994) and were diagnosed using the Structured Clinical Interview for Mental Disorders, research version 2.0, (SCID-I). Diagnosis was blind to genotype. Most of the patients were female (N ¼ 130; 91%), and 20% of the studied AN sample has been described and assessed in a previous report. 29 The Once sequence variants were identified, their effect on the restriction map was determined by the DNA Strider 1.0.1 software. Then, 3 ml of the corresponding PCR products were digested overnight at 371C in a total volume of 10 ml with 5 U of HinfI (Biolabs) for À270C/T, DdeI (Roche) for À256G/A and NlaIII (Biolabs) for Val66Met and resolved on 12% polyacrylamide gels (19 : 1).
Statistical analysis
The power analysis was performed post hoc on the ED group as a whole with the Power Calculator software (Department of Statistics of the University of Los Angeles; http://ebook.stat.ucla.edu/calculators/powercalc) assuming a lifetime risk of 6% for first relatives of a patient with ED and a significance level of 0.05. Average minimum BMI, age at assessment and duration of the disorder in each studied group were measured by the statistical package SPSS 10.0. The distribution of genotypes for the different populations was tested for the Hardy-Weinberg equilibrium by a w 2 analysis using the INSTAT Graphpad software. As the sample size was too small to use a standard w 2 test, the comparison of both allelic and genotypic frequencies between the control and the ED groups was assessed by the two-tailed Fisher's exact test using the statistical package SPSS 10.0. Patients with ED were analyzed as a unique group and also subgrouped according to the clinical subtype (AN, ANR, ANBP and BN) in all statistical tests. As we subdivided our ED patients into four diagnostic subgroups and two genetic markers were analyzed, the Bonferroni correction was used for w 2 test and corrected P-values were considered significant when below 0.006. Haplotype association analysis and linkage disequilibrium tests were performed using the pmplus program. 30 Differences in mean scores of EDs-related phenotypes, such as MBMI and AAOC, were assessed by t-tests using the statistical package SPSS 10.0. Significance levels were set at Po0.05.
